Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Molbio Diagnostics Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹807
Per ShareLot Size
18 Shares
Minimum Investment
₹14,526
Issue Size
₹939.7 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
44.89%
Promoter Holding (Post-Issue)
41.29%
Issue Type
Book Building
ISIN
INE869T01028
We are an innovative point-of-care diagnostics company focused on expanding access to accurate, rapid and costeffective healthcare technologies to diagnose infectious and non-communicable diseases. Our portable and battery operated `Truenat' platform facilitates diagnosis using our disease-specific `Truenat' test kits within an hour and enables screening and diagnosis for 30 diseases, including tuberculosis, COVID, Hepatitis B and C, Human immunodeficiency virus, and Human Papillomavirus, as of March 31, 2025. We also offer devices, enabling radiology, digital pathology and breast health screening. We offer our products globally to public health programs, diagnostic laboratories, and private and public hospitals.
The global point-of-care testing ("POCT") market stands at Rs.2,350.8 billion (infectious and non-infectious diseases), projected to grow at 18.7% CAGR to reach at Rs.5,555.6 billion by 2029. Infectious disease testing constitutes 31.4% of the global POCT market. POCT market in India stands at approximately Rs.198.5 billion in Fiscal 2025, projected to grow at 17.3% CAGR to reach at approximately 440.9 billion by Fiscal 2030. Of which, the infectious POCT market is estimated to have a market potential of Rs.88.2 billion in Fiscal 2025 and is projected to reach Rs. 236.6 billion by Fiscal 2030.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 11,646,246 equity shares of face value of Re. 1 each of the company ("Equity Shares") for cash at a price of Rs. 807 per equity share (including a share premium of Rs. 806 per equity share) ("Offer Price") aggregating to Rs. 939.70 Crores ("Offer"). The offer comprises a fresh issue of 2,480,246 equity shares of face value of Re. 1 each aggregating to Rs. 200.00 Crores ("Fresh Issue") and an offer for sale of 9,166,000 equity shares of face value of Re. 1 each ("Offered Shares") aggregating to Rs. 739.70 Crores, comprising 1,811,000 equity shares of face value of Re. 1 each aggregating to Rs. 146.15 Crores by Exxora Trading LLP, 1,221,000 equity shares of face value of Re. 1 each aggregating to Rs. 98.54 Crores by Chandrasekhar Bhaskaran Nair (Jointly Held with Anita Angela Chandrasekhar), 48,000 equity shares of face value of Re. 1 each aggregating to Rs. 3.87 Crores by Abdul Qadir Mohamed Theruvath, 193,000 equity shares of face value of Re. 1 each aggregating to Rs. 15.58 Crores by Chewbacca Services Limited, 902,000 equity shares of face value of Re. 1 each aggregating to Rs. 72.79 Crores by J. Guru Dutt (Jointly Held with Sandhya Guru Dutt), 1,125,000 equity shares of face value of Re. 1 each aggregating to Rs. 90.79 Crores by Gopalkrishna Mangalore Kini, 902,000 equity shares of face value of Re. 1 each aggregating to Rs. 72.79 Crores by Gopalakrishna Sampathgiri (Jointly Held with Jayshree Sampathgiri), 1,000,000 equity shares of face value of Re. 1 each aggregating to Rs. 80.7 Crores by India Business Excellence Fund III, 17,000 equity shares of face value of Re. 1 each aggregating to Rs. 1.37 Crores by M Ganesh Kamath, 248,000 equity shares of face value of Re. 1 each aggregating to Rs. 20.01 Crores by M.A. Rohit, 202,000 equity shares of face value of Re. 1 each aggregating to Rs. 16.30 Crores by M.A. Sharath, 451,000 equity shares of face value of Re. 1 each aggregating to Rs. 36.40 Crores by M.A. Usha Rani, 452,000 equity shares of face value of Re. 1 each aggregating to Rs. 36.48 Crores by Sangeetha M Kini, 97,000 equity shares of face value of Re. 1 each aggregating to Rs. 7.83 Crores by Shaheeda Abdul Kader, 226,000 equity shares of face value of Re. 1 each aggregating to Rs. 18.24 Crores by Shruti G Kini, 193,000 equity shares of face value of Re. 1 each aggregating to Rs. 15.58 Crores by Sujay Limited, and 78,000 equity shares of face value of Re. 1 each aggregating to Rs. 6.30 Crores by Vivek Devaraj (together, the "Selling Shareholders", and such offer for sale of equity shares by the selling shareholders, the "Offer for Sale"). This offer includes a reservation of 20,519 equity shares of face value of Re. 1 each aggregating to Rs. 1.5 (constituting 0.02% of the post-offer paid-up equity share capital) for subscription by eligible employees (the "Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer would constitute 10.11% and 10.09%, respectively, of the company post-offer paid-up equity share capital. Price Band: Rs. 807 per equity share of face value of Rs. 1 each. The floor price 807 times the face value of the equity shares, respectively. Bids can be made for a minimum of 18 equity shares of face value of Rs. 1 each and in multiples of 18 equity shares of face value of Rs. 1 each thereafter. A discount of Rs. 76.00 per equity share is being offered to eligible employees bidding in the employee reservation portion.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Our Company was originally incorporated as `Molbio Diagnostics Private Limited' at Panaji, as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 20, 2000, issued by the RoC. Thereafter, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of our Shareholders held on November 22, 2024, and the name of our Company was changed to Molbio Diagnostics Limited, and a fresh certificate of incorporation dated January 16, 2025 was issued to our Company by the RoC.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
*Subject to approvals and market conditions.